Koh Lee Jin, Martz Karen, Blydt-Hansen Tom David
Paediatric Nephrology, National University Hospital System, Singapore, Singapore.
Pediatric Nephrology, BC Children's Hospital, Vancouver, British Columbia, Canada.
Pediatr Transplant. 2019 Aug;23(5):e13469. doi: 10.1111/petr.13469. Epub 2019 Jun 6.
With improved outcomes for children transplanted with FSGS since previous NAPRTCS registry reports, this study re-evaluates the association of living donation, immunosuppression, and DGF on graft survival.
Patients transplanted between 2002 and 2016, comparing FSGS diagnosis vs other glomerular diseases.
Primary outcomes were allograft survival and FSGS recurrent-free graft survival. Potential risk factors were obtained at the time of transplant and up to 30 days post-transplantation. Analysis considered a priori that DGF may be a proxy for severe FSGS recurrence. Multivariable survival models for outcome were tested for sensitivity without/with DGF to determine features independent of recurrence.
From the larger cohort of 3010 patients, 5-year graft survival in children with FSGS (n = 455) was worse (74.3%) compared with other glomerular diseases (87.1%, n = 690) (HR 1.45, P = 0.033). Modeling all glomerular diseases, survival risk was associated with deceased donor (HR 1.83, P = 0.002), re-transplantation (HR 1.58, P = 0.013), and recipient age (HR 1.06/y, P = 0.002). The living donor advantage was not confirmed in a FSGS model (HR 1.51 for deceased, P = 0.12). DGF was highly associated with graft failure (HR 4.39, P < 0.001) and independent of re-transplant history but not FSGS diagnosis. Induction agents or primary immunosuppression choices were not associated with survival.
Graft survival rates have improved since the previous report. Living donor did not predict graft failure, but there remains no survival advantage. DGF was the primary independent predictor for graft loss secondary to FSGS recurrence, consistent with DGF being a proxy for severe recurrent disease.
自上一份北美儿科肾脏移植协作研究(NAPRTCS)登记报告以来,儿童局灶节段性肾小球硬化(FSGS)移植的预后有所改善,本研究重新评估活体供肾、免疫抑制和移植肾功能延迟恢复(DGF)对移植肾存活的影响。
2002年至2016年间接受移植的患者,比较FSGS诊断与其他肾小球疾病。
主要结局为移植肾存活和无FSGS复发的移植肾存活。在移植时及移植后30天内获取潜在风险因素。分析预先认为DGF可能是严重FSGS复发的替代指标。对结局的多变量生存模型在有/无DGF的情况下进行敏感性测试,以确定独立于复发的特征。
在3010例患者的更大队列中,FSGS患儿(n = 455)的5年移植肾存活率(74.3%)低于其他肾小球疾病(87.1%,n = 690)(风险比[HR] 1.45,P = 0.033)。对所有肾小球疾病进行建模,生存风险与 deceased donor(HR 1.83,P = 0.002)、再次移植(HR 1.58,P = 0.013)和受者年龄(HR 1.06/年,P = 0.002)相关。在FSGS模型中未证实活体供肾的优势(deceased的HR 1.51,P = 0.12)。DGF与移植肾失败高度相关(HR 4.39,P < 0.001),且独立于再次移植史,但与FSGS诊断无关。诱导剂或初始免疫抑制选择与生存无关。
自上次报告以来,移植肾存活率有所提高。活体供肾不能预测移植肾失败,但仍无生存优势。DGF是FSGS复发导致移植肾丢失的主要独立预测因素,这与DGF是严重复发性疾病的替代指标一致。